Solid Lipid Nanoparticle (SLNP) Nammisome formulated with Doxorubicin Prodrug (IC1)
Why a Doxorubicin Prodrug? Doxorubicin is a widely used immunogenic cell death (ICD) inducing chemotherapeutic drug. Doxil, the liposome-encapsulated form of Doxorubicin, shows superiority to free Doxorubicin clinical performance in a variety of neoplastic conditions but still faces challenges. SLNP-IC1 is a novel Prodrug of Doxorubicin formulated as an SLNP, with an improved therapeutic window in preclinical studies and an easier, more reproducible manufacturing process than Doxil.
Target Indications: Liposomal Doxorubicin has been approved in the US for ovarian (disease progression/recurrence after platinum-based chemo), Kaposi’s sarcoma (after the failure of prior systemic chemo or intolerance to it), and multiple myeloma (in combination with bortezomib). SLNP-IC1 may therefore be applicable to these indications, and potentially to other solid tumors as well.
Demonstrated Improved Stability, Efficacy, and Safety vs. Doxil
Solid Lipid Nanoparticle formulated IC1 Prodrug dramatically reduces release of free Doxorubicin in human serum compared to liposomal Doxorubicin (LNP-DOX)
Tumor growth inhibition at equivalent dose in vivo (EMT-6 breast cancer murine tumor model) presumably due to enhanced exposure of the nanocarrier associated Doxorubicin
At a significantly higher dose of 12 mg/kg of Doxorubicin equivalents, mice treated with the Nammisome-formulated Doxorubicin exhibit less body weight loss, indicating reduced toxicity